Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sen. Gregg Eyes Flu Vaccine Manufacturer Liability Protections In Biodefense Bill

This article was originally published in The Pink Sheet Daily

Executive Summary

The Senate Appropriations/Homeland Security Subcommittee chairman indicates he may consider stronger liability protections for flu vaccine manufacturers in S 3, his biodefense bill.

You may also be interested in...



HHS In Final Phases Of Acquiring Additional Countermeasures Under BioShield

Department is nearing contract completion for anthrax therapeutics, botulinum antitoxin and a next-generation smallpox vaccine. HHS has awarded three contracts since passage of BioShield legislation, for recombinant protective antigen anthrax vaccine, potassium iodide and anthrax vaccine adsorbed.

HHS In Final Phases Of Acquiring Additional Countermeasures Under BioShield

Department is nearing contract completion for anthrax therapeutics, botulinum antitoxin and a next-generation smallpox vaccine. HHS has awarded three contracts since passage of BioShield legislation, for recombinant protective antigen anthrax vaccine, potassium iodide and anthrax vaccine adsorbed.

Population-Wide Smallpox Vaccination Urged At Senate Hearing

Smallpox vaccination should be reinstated for the entire U.S. population, MIT’s Deutch suggests. Additional research on other biological threats is called for; federal funding is recommended instead of relying on industry initiative, due to lack of market incentives.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel